Valeant Pharmaceuticals , long Wall Street’s favorite drug maker, has finally been brought low. On Tuesday a remarkably awkward earnings announcement—epitomized by a $600 million typo in the company’s financial guidance—revealed that sales will be more than $1 billlion lower than expected this year and that the company will fail to file its annual report on time, triggering notices of default from bondholders.
